Despite a highlight story on 60 Minutes last month, fluvoxamine, a drug typically used to treat obsessive-compulsive disorder (OCD), is still just a brief mention in the "cytokine inhibitors" section in the New York Times' "Coronavirus Drug and Treatment Tracker."For now, it makes sense.
Fluvoxamine, a serotonin reuptake inhibitor (SSRI), has shown promise in two smaller studies, but larger trials have not been published yet.Even if the drug becomes a more mainstream treatment for COVID-19, one expert says any demand surge is not expected to result in shortages.COVID-19 treatment potentialAs 60 Minutes tells it, the first COVID-19–related fluvoxamine study began because Angela Reiersen, MD, MPE, was reflecting on potentially relevant